Comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 vs 2 Hydroxyphenylacetic Aciduria C5937087
Clinical comparison between 3 Beta Hydroxysteroid Dehydrogenase Deficiency and 2 Hydroxyphenylacetic Aciduria for differential diagnosis and treatment planning.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
2 Hydroxyphenylacetic Aciduria C5937087
A rare metabolic disorder where the body cannot properly process certain acids. It may cause neurological issues and is typically identified in infancy. Management involves diet modifications and supportive care.
6 comparison axes
Onset
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
2 Hydroxyphenylacetic Aciduria C5937087
0-null
Onset patterns differ
Severity
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
2 Hydroxyphenylacetic Aciduria C5937087
moderate
Different severity levels
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
2 Hydroxyphenylacetic Aciduria C5937087
Chronic
Differing course
Communicable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
2 Hydroxyphenylacetic Aciduria C5937087
No
Different transmission
Body System
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Same/different system
Category
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
2 Hydroxyphenylacetic Aciduria C5937087
metabolic
Different category
Bottom line
3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 and 2-hydroxyphenylacetic-aciduria-C5937087 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 2 Hydroxyphenylacetic Aciduria C5937087 | Discriminating power |
|---|---|---|---|
| Genital and adrenal features | May include ambiguous genitalia and adrenal hormone imbalance. | Genital or adrenal steroid disease is not described in the source. | High |
| Neurologic or metabolic features | Neurologic disease is not the defining feature in the supplied description. | May involve neurologic issues and impaired processing of certain acids, often noted in infancy. | Moderate |
| Acute illness pattern | Salt-wasting crises are a described risk in a severe chronic disorder. | An acute crisis pattern is not established; severity is described as moderate. | Moderate |
When to favor each condition
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Suspected adrenal insufficiency with genital difference
This pattern aligns with the supplied endocrine phenotype rather than aciduria.
Moderate
Salt-wasting illness with hormonal imbalance
The source specifically links the left condition to salt-wasting and hormone replacement.
Moderate
Confirmed disorder of adrenal steroid production
The left item is described as a genetic adrenal hormone-production disorder.
High
Choose 2 Hydroxyphenylacetic Aciduria C5937087 when
Infancy with neurologic concerns and abnormal acid results
The source describes a metabolic acid-processing problem typically identified in infancy.
Moderate
Isolated 2-hydroxyphenylacetic acid finding
An abnormal urine result is not itself a diagnosis and needs clinician interpretation.
High
Metabolic evaluation without adrenal or genital features
Diet modification and supportive care are the described management approach.
Low
How key tests differ
| Test | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 2 Hydroxyphenylacetic Aciduria C5937087 | Interpretation |
|---|---|---|---|
| Adrenal steroid assessment | Abnormal adrenal hormone production may be found; exact cutoffs are not supplied. | Not described as the defining test. | Use to investigate an endocrine disorder, not to infer the metabolic finding. |
| Urine organic acid testing | Not identified as the primary test in the source. | May show 2-hydroxyphenylacetic acid, which can be an abnormal result rather than a diagnosis. | Specialist review should consider possible causes and clinical context. |
| Genetic testing | May support the rare genetic adrenal disorder when clinically indicated. | A specific genetic basis is not established by the supplied data. | Do not assign a gene or diagnosis without appropriate clinical confirmation. |
Prognosis comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- A severe chronic endocrine disorder; individual outcome is not established here.
- Factors
- Hormone replacement, crisis prevention, and monitoring are described management needs.
2 Hydroxyphenylacetic Aciduria C5937087
- Outcome
- A moderate chronic metabolic condition or finding; prognosis is not established.
- Factors
- Diet modification, supportive care, and neurologic follow-up may be relevant.
Time frame: Long-term follow-up may be needed, but the exact course is not established.
Severity, associated complications, early recognition, and specialist care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Salt-wasting crisis | A described potential emergency. Not established in the supplied description. Vomiting, poor feeding, lethargy, or dehydration needs urgent assessment. |
| Difference in sex development | Ambiguous genitalia may occur. Not described. Endocrine and multidisciplinary counseling may be needed when present. |
| Neurologic complications | Not the defining complication in the source. Neurologic issues may occur, but their range is not established. Developmental follow-up is appropriate if concerns are present. |
Patient education highlights
- HighNot a self-diagnosis
These rare labels and abnormal tests require specialist interpretation before treatment decisions.
- HighEmergency warning signs
Poor feeding, vomiting, lethargy, or dehydration need urgent care, particularly if adrenal disease is suspected.
- MediumDifferent management approaches
The left condition may need hormone replacement and monitoring; the right may need diet changes and supportive care. No doses are provided.